GBA1 and Parkinson disease: [18F]-fluorodeoxyglucose (FDG)-PET studies in genetic PD patients have documented widespread metabolic alterations in GBA1-PD patients with N370S/R496H mutations encompassing frontal, parietal, striatal, and thalamic brain regions [29].